|
ATP8B1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.31210000040316E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.60990999999999E-05 |
| Normal-vs-Stage2 |
4.222000E-03 |
| Normal-vs-Stage3 |
3.97960000508846E-08 |
| Normal-vs-Stage4 |
3.6033000000435E-06 |
| Stage1-vs-Stage2 |
5.615400E-01 |
| Stage1-vs-Stage3 |
1.058440E-01 |
| Stage1-vs-Stage4 |
2.055800E-01 |
| Stage2-vs-Stage3 |
1.037790E-01 |
| Stage2-vs-Stage4 |
1.524410E-01 |
| Stage3-vs-Stage4 |
8.760400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.09770000000786E-06 |
| Normal-vs-AfricanAmerican |
1.154490E-02 |
| Normal-vs-Asian |
4.78210004928314E-09 |
| Caucasian-vs-AfricanAmerican |
6.270200E-01 |
| Caucasian-vs-Asian |
1.234380E-02 |
| AfricanAmerican-vs-Asian |
9.968100E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.03529999998064E-06 |
| Normal-vs-Female |
1.25009999996095E-06 |
| Male-vs-Female |
5.549200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.79513999999381E-05 |
| Normal-vs-Age(41-60Yrs) |
9.2390999995029E-07 |
| Normal-vs-Age(61-80Yrs) |
2.38559999999888E-05 |
| Normal-vs-Age(81-100Yrs) |
1.561850E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.088000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.537600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.811800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.017400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.892800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.315200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.938030E-01 |
| Classical-VS-Follicular |
1.050260E-02 |
| Classical-VS-Other |
5.907800E-01 |
| Classical-VS-Normal |
1.44930000001153E-07 |
| Tall-VS-Follicular |
2.923200E-03 |
| Tall-VS-Other |
9.602200E-01 |
| Tall-VS-Normal |
6.35270000048926E-07 |
| Follicular-VS-Other |
2.104200E-01 |
| Follicular-VS-Normal |
3.749600E-02 |
| Other-VS-Normal |
1.077550E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.84200000000035E-05 |
| Normal-vs-N1 |
5.33809999536672E-08 |
| N0-vs-N1 |
2.968000E-02 |
|
|
